



Measles Outbreaks, Vaccine Hesitancy, and Federal Policy Options

Updated June 3, 2019

As of May 31, 2019, 981 cases of measles across 26 U.S. states have been reported to the Centers for Disease Control and Prevention (CDC)—the [highest annual number of measles cases](#) since 1992 (with no deaths reported). **Figure 1** shows annual measles cases in the past 10 years.

Measles is a [highly contagious viral illness](#) that can lead to pneumonia, encephalitis (infection of the brain), and, rarely, death. Certain groups are at greater risk for complications (e.g., children under 5 and adults over 20 years of age). No specific treatment exists, but it can be prevented with a vaccine.


According to CDC, before a vaccine became available in 1963, there were an estimated 3 million to 4 million annual U.S. measles cases, with an annual average of approximately 48,000 hospitalizations and 400-500 hundred deaths. Widespread vaccination has curtailed *ongoing measles transmission*.

Accordingly, measles was [declared eliminated](#) (i.e., no ongoing disease transmission for at least 12 months) in the United States in 2000, and efforts to [eliminate measles transmission worldwide](#) (called *eradication*) continue. Nonetheless, U.S. [measles outbreaks](#) are occurring again, principally due to repeated reintroduction from international travelers and an increase in communities with low vaccination rates. If U.S. outbreaks continue, measles [may lose its elimination status](#).

Congressional Research Service

<https://crsreports.congress.gov>

IN11125

Figure I. Annual U.S. Measles Cases Reported to CDC by States, 2010-2019

Source: Developed by CRS from CDC, “Measles Cases and Outbreaks,” <https://www.cdc.gov/measles/cases-outbreaks.html>.

Vaccine Use and Hesitancy

Immunization to measles is provided by a *trivalent* vaccine that protects against measles, mumps, and rubella using live *attenuated* (weakened) virus. It is commonly called the “MMR” vaccine. Two formulations are [currently licensed](#) (i.e., authorized for marketing) by the U.S. Food and Drug Administration (FDA). Each contains attenuated measles virus along with one or more additional virus types.

The federal [Advisory Committee on Immunization Practices](#) (ACIP) makes recommendations for the clinical use of licensed vaccines. In general, the ACIP and CDC recommend [two doses of MMR](#) or comparable vaccine for children: the first dose between 12 and 15 months of age, and another between 4 and 6 years of age. The vaccine is not recommended for some children with chronic illnesses, including illnesses that compromise their immune systems.

[CDC reports](#) that in 2017, about 91.5% of children aged 19-35 months had received at least one dose of MMR vaccine. Although this coverage seems high, measles is so highly contagious that it may not be sufficient to prevent spread of the disease. [A recent model](#) determined that 93%-95% of the population must be vaccinated to prevent measles transmission. This level of immunization in the population would be needed to protect those who cannot be vaccinated (i.e., *herd immunity*).

To control vaccine-preventable diseases, [all states require](#) specified vaccination for students. This [exercise of states’ police power](#) has been upheld since the Supreme Court decision in *Jacobson v. Massachusetts* in 1905. All states allow exemptions for *medical reasons*; 47 states allow them for *religious beliefs*; and 16 states allow so-called *philosophical or “personal belief”* exemptions. [Implementation of these exemptions varies](#); some states require a parental affidavit for exemption, or impose movement restrictions on unvaccinated children during outbreaks, for example. Even though state vaccination requirements have long withstood various constitutional challenges, there is [a portion of people](#) who consider vaccine mandates to infringe on personal liberty. In addition, a long-standing bioethics principle holds that governments should use the [least restrictive means necessary](#) to achieve a public health objective.

[Nonmedical exemptions \(NME\)](#) from vaccine mandates tend to occur in [geographic clusters](#) and are associated with higher rates of vaccine preventable disease. High use of NMEs has been [linked to vaccine](#)

hesitancy—the delay or refusal of vaccines despite their availability. [Pediatricians report](#) a rise in vaccine refusals in recent years and added time spent addressing parental concerns. [Surveys of parents](#) show the following drivers of vaccine hesitancy: the large number of injections; moral or religious objections; cost or other access problem; lack of information; and concerns about side effects, particularly autism.

Concern that vaccines cause autism is often attributed to a 1998 study suggesting an association of autism with MMR vaccination. The study was later [deemed flawed and retracted](#). Subsequent studies and reviews (such as [a meta-analysis involving over 1 million children](#) and a recent [nationwide study in Denmark](#)) have not supported such an association.

Federal Policy Options

The federal government [supports immunization](#) in numerous ways, among others, by [licensing vaccines](#) shown to be safe and effective; by purchasing or paying for vaccines for [low-income children](#) and [state immunization programs](#); by supporting [ongoing research](#) and the work of several advisory committees to help guide policy and immunization practices; and by [tracking](#) and administering a [compensation program](#) for vaccine-associated adverse events.

The federal government currently addresses vaccine hesitancy in several ways. [CDC](#), the [Department of Health and Human Services](#) (HHS), and other federal agencies provide educational material for parents, providers, and others. Several federal grants may be used to support multi-component interventions—education combined with incentives, home visits, and reminders—which [have proven effective](#) at increasing vaccination rates. Also, [CDC supports research](#) into the nature of vaccine hesitancy and the means to overcome it.

The current measles outbreaks have prompted discussions and recent [congressional hearings](#) on additional ways that the federal government could address vaccine hesitancy and bolster public trust in vaccines. Among them

- Conditioning the [receipt of federal immunization assistance](#) upon a state’s prohibition of NME. Whether such an intervention could be crafted so as to [not be overly coercive](#) is not clear.
- Supporting additional counseling time spent by health care providers, whom [parents say are a trusted source of information](#), through payment policy or other interventions.
- [Doubling the number](#) of [special masters](#) who adjudicate claims for the [National Vaccine Injury Compensation Program](#) (VICP), in order to address a claims backlog.
- Strengthening [Immunization Information Systems](#) (IIS)—population-based electronic health record (EHR) databases—through [enhancing interoperability, standardization, and data sharing](#). Through IIS, states and CDC can collect real-time data on vaccination coverage, monitor for safety, and implement reminder systems.

Author Information

Kavya Sekar
Analyst in Health Policy

Sarah A. Lister
Specialist in Public Health and Epidemiology

Disclaimer

This document was prepared by the Congressional Research Service (CRS). CRS serves as nonpartisan shared staff to congressional committees and Members of Congress. It operates solely at the behest of and under the direction of Congress. Information in a CRS Report should not be relied upon for purposes other than public understanding of information that has been provided by CRS to Members of Congress in connection with CRS's institutional role. CRS Reports, as a work of the United States Government, are not subject to copyright protection in the United States. Any CRS Report may be reproduced and distributed in its entirety without permission from CRS. However, as a CRS Report may include copyrighted images or material from a third party, you may need to obtain the permission of the copyright holder if you wish to copy or otherwise use copyrighted material.